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Abstract
Background: The nation-wide concern over methicillin-resistant Staphylococcus aureus (MRSA)
has prompted many clinicians to use vancomycin when approaching patients with suspected
staphylococcal infections. We sought to characterize the epidemiology of community-onset S.
aureus infections in hospitalized children to assist local clinicians in providing appropriate empiric
antimicrobial therapy.
Methods: From January 2005–June 2008, children (0–18 years old) admitted to the Children's
Hospital of Illinois with community-onset S. aureus infections were identified by a computer-
assisted laboratory-based surveillance and medical record review.
Results: Of 199 patients, 67 (34%) had invasive infections, and 132 (66%) had skin and soft tissue
infections (SSTIs). Among patients with invasive infections, S. aureus isolates were more likely to be
susceptible to methicillin (MSSA 63% vs. MRSA 37%), whereas patients with SSTIs, S. aureus isolates
were more likely to be resistant to methicillin (MRSA 64% vs. MSSA 36%). Bacteremia and
musculoskeletal infections were the most common invasive infections in both groups of S. aureus.
Pneumonia with empyema was more likely to be caused by MRSA (P = 0.02). The majority (~90%)
of MRSA isolates were non-multidrug resistant, even in the presence of healthcare-associated risk
factors.
Conclusion: Epidemiological data at the local level is important for antimicrobial decision-making.
MSSA remains an important pathogen causing invasive community-onset S. aureus infections among
hospitalized children. In our hospital, nafcillin in combination with vancomycin is recommended
empiric therapy in critically ill patients with suspected invasive staphylococcal infections. Because
up to 25% of MSSA circulating in our area are clindamycin-resistant, clindamycin should be used
cautiously as empiric monotherapy in patients with suspected invasive staphylococcal infections.
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Background
Infections caused by community-associated methicillin-
resistant  Staphylococcus aureus (CA-MRSA) have been
increasingly reported worldwide. Such isolates differ from
healthcare-associated MRSA (HA-MRSA) by a distinct
antimicrobial susceptibility pattern, usually being suscep-
tible to non-β-lactam antimicrobial agents and having dif-
ferent genetic backgrounds as determined by SCCmec
elements, multilocus sequence types (MLST), and pulsed-
field gel electrophoresis [1-4]. Many studies suggest that
CA-MRSA have replaced their methicillin-susceptible
counterparts as the major cause of skin and soft tissue
infections and other invasive diseases [5-9]. These find-
ings have important clinical implications for the selection
of antimicrobial agents. In areas where CA-MRSA is com-
mon, antimicrobial agents that are active against CA-
MRSA should be advocated for empiric treatment of
patients with potential S. aureus infections, until the cul-
ture and susceptibility results are available [5,8-10].
It is important to note that most data on CA-MRSA come
from large tertiary care centers, many of which are located
in large metropolitan areas. Thus, these data may not be
generalizable to other hospitals in smaller, mid-size or
more rural communities. Knowledge of the antimicrobial
susceptibility patterns at the local level is essential for
selecting appropriate empiric therapy of the wide variety
of S. aureus infections. At the Children's Hospital of Illi-
nois (CHOI), we have observed significant numbers of
patients with community-onset infections caused not
only by MRSA but also by MSSA. We thus needed a better
understanding of the epidemiology of community-onset
S. aureus infections in children admitted to our institu-
tion.
Methods
Setting
The Children's Hospital of Illinois at OSF Saint Francis
Medical Center has 127 inpatient beds and about 5000
admissions annually. It serves as the academic, tertiary
care referral center for the central region of Illinois.
Study design
A database of laboratory records from the OSF System
Laboratory was used to identify pediatric patients 18 years
of age or younger who were hospitalized from January 1,
2005 through June 30, 2008 and had microbiologic spec-
imens that yielded S. aureus. For each case of S. aureus iso-
lated from clinical specimens, the relevant medical
information was examined, including diagnosis, onset of
infection, infection sites, demographics (age, gender),
underlying illnesses, risk factors for healthcare-associated
infections, and isolate antimicrobial susceptibility. The
study was approved by the Peoria Institutional Review
Board.
Definitions
Patients with community-onset S. aureus infections were
included if (a) the patients' isolates were recovered within
48 hours of admission, based on the criteria established
by the Centers for Disease Control and Prevention (CDC,
Atlanta) or if (b) their isolates were obtained after 48
hours of admission but patients had clinical evidence of
diseases prior to admission.
A case of invasive infection was defined by 1 or more of
the following conditions: bacteremia, endocarditis, pneu-
monia, lymphadenitis, septic arthritis, osteomyelitis, or
another illness in which S. aureus was isolated from nor-
mally sterile body fluids. Infections involving the skin or
soft tissue structures such as abscess or cellulitis were
regarded as skin and soft tissue infections (SSTIs).
Patients were excluded if they had positive culture results
but no signs of infection; or if a diagnosis of MRSA infec-
tion was made on the basis of positive MRSA screening
cultures (nose, axilla, perineum, or rectum); or if the diag-
nosis of staphylococcal pneumonia was based solely on
the isolation of S. aureus from a tracheal aspirate or spu-
tum. Patients with orbital or otogenic infections were
excluded if the S. aureus isolates were recovered from the
swabs of the eye or ear drainage only.
For individuals with multiple hospital admissions for
SSTIs during a single year, data were obtained from the
first hospitalization. Risk factors for healthcare-associated
infections included hospitalization or surgery in the pre-
ceding 12 months, the presence of an indwelling catheter
or a percutaneous device, or frequent exposure to a health-
care facility related to an underlying condition. A hospital
birth without any postnatal complications was not con-
sidered a risk factor.
Antimicrobial susceptibility testing
An automated system (Vitek 2; bioMérieux) was used to
determine the antimicrobial susceptibility profile of S.
aureus isolates in accordance with the recommendations
of the Clinical and Laboratory Standards Institute. For iso-
lates that tested resistant to erythromycin but susceptible
to clindamycin, a D-test was performed to detect induci-
ble resistance to clindamycin. Among MRSA, multidrug
resistance (MDR) was used and defined as resistance to
three or more non-β-lactam antimicrobial agents (cipro-
floxacin or levofloxacin, clindamycin, erythromycin, gen-
tamicin, tetracycline, trimethoprim-sulfamethoxazole,
rifampin, vancomycin).
Statistical analyses
Differences in variables between groups were calculated
by chi-square test or Fisher's exact test, as appropriate. P <
0.05 was considered statistically significant.BMC Infectious Diseases 2009, 9:112 http://www.biomedcentral.com/1471-2334/9/112
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Results
We identified 212 hospitalized pediatric patients whose S.
aureus infections were considered community-onset. Thir-
teen patients were excluded: four patients had no clinical
evidence of diseases and received no antibiotic therapy,
including three with a positive blood culture and one who
grew S. aureus from the gall bladder after elective cholecys-
tectomy; nine had invasive diseases, but their infections
could not be definitely proved to be caused by S. aureus,
including three with orbital cellulitis, two with otomas-
toiditis, and one each with pneumonia, retropharyngeal
abscess, possible staphylococcal scalded skin syndrome,
and fasciitis of the chest wall.
Of the remaining 199 patients, 67 (34%) had invasive
infections and 132 (66%) had SSTIs. These two groups
were significantly different (P < 0.01) with regard to the
proportion of MSSA and MRSA isolates (Table 1). Among
patients with invasive infections, S. aureus isolates were
more likely to be susceptible to methicillin [MSSA 42/67
(63%) vs. MRSA 25/67 (37%)]. In patients with SSTIs, S.
aureus isolates were more likely to be resistant to methicil-
lin [MSSA 47/132 (36%) vs. MRSA 85/132 (64%)]. The
semi-annual distribution of cases and admission rates
(number of cases per 100 hospital admissions) are shown
in Figure 1. Overall, the number of community-onset
infections caused by MRSA increased yearly, but the
increase was mainly due to SSTIs.
Demographic and clinical features of patients are summa-
rized in Table 1. There was a significant age group differ-
ence (P < 0.01) between patients with MSSA and MRSA
infections. MSSA infections were common in young chil-
dren (4–59 mo) and teenagers (11–18 y), whereas MRSA
infections occurred more often in young children (4–59
mo). Characteristics of invasive infections and healthcare-
associated risk factors are shown in Table 2. Bacteremia
and musculoskeletal infections were the most common
invasive infections caused by S. aureus, regardless of its
methicillin susceptibility. Fourteen patients (9 MSSA and
5 MRSA) had S. aureus bacteremia complicated with one
or more site of infection. Among patients who had inva-
sive infections, pneumonia with pleural empyema was
more likely to be caused by MRSA (P = 0.02), although
there were only 9 patients with pneumonia in this study.
In addition, among patients with invasive infections, only
29 patients had a documented history whether or not they
had prior MRSA skin infections or contact with MRSA
infected persons or family members before the onset of
the illness. Such history was found in 67% (12/18) of
patients with invasive MRSA infections, and in only 9%
(1/11) of patients with invasive MSSA infections (P  <
0.01). The most commonly affected sites of SSTIs were
perineum and buttocks (45%), especially in the 4–59
months age group.
Exposure to healthcare-associated risk factors was not sig-
nificantly different between MSSA and MRSA groups (P =
0.57). In the subgroup of patients who had no docu-
mented healthcare-associated risk factors, bacteremia (n =
9) and musculoskeletal infections (n = 9) remained the
most common invasive infections caused by MSSA,
whereas pneumonia with pleural empyema (n = 7) was
the most common invasive infection caused by MRSA.
Clindamycin resistance (constitutive and inducible resist-
ance) was observed in 15% (13 of 89) of MSSA. However,
the proportion of MSSA resistant to clindamycin was 21%
(10 of 47) among isolates causing SSTIs, but was not sig-
nificantly different (7%, 3 of 42) among isolates causing
invasive infections (P = 0.08). Antimicrobial susceptibility
testings of MRSA isolates are shown in Additional file 1.
The majority of MRSA isolates were non-MDR (88% vs.
93% in patients with and without healthcare-associated
risk factors, respectively) (Table 3). Only 9 MRSA isolates
were MDR, of which 4 were in patients who had health-
care-associated risk factors. There were no significant dif-
ferences in healthcare-associated risk factors among
patients who had infections caused by non-MDR (P  =
0.20) or MDR (P = 0.21) MRSA. In our population, pres-
ence of risk factors for healthcare-associated infections
was not associated with MDR MRSA infections (P = 0.45).
Discussion
In this study, the percentages of S. aureus causing SSTIs
that are methicillin-resistant have increased yearly and
accounted for 70–75% during 2007–2008. This finding
was not different from other regions of the United States.
Nevertheless, MSSA remains a common pathogen causing
Table 1: Demographic and clinical features of patients with 
community-onset S. aureus infections.
No. (%)
Variables MSSA
n = 89
MRSA
n = 110
P
Age
0–3 mo 11 (12.4) 7 (6.4)
4–59 mo 42 (47.2) 82 (74.5) < 0.01
5–10 y 12 (13.5) 10 (9.1)
11–18 y 24 (26.9) 11 (10.0)
Gender
Male 46 (51.7) 47 (42.7) 0.25
Female 43 (48.3) 63 (57.3)
Clinical manifestations
Skin and soft tissue infections 47 (52.8) 85 (77.3) < 0.01
Invasive infections 42 (47.2) 25 (22.7)
Healthcare-associated risk factors
Present 31 (34.8) 33 (30.0) 0.57
Absent 58 (65.2) 77 (79.0)BMC Infectious Diseases 2009, 9:112 http://www.biomedcentral.com/1471-2334/9/112
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invasive community-onset S. aureus infections. It is of
note that, in year 2007, there may have been a trend
toward an increase in invasive MRSA infections (Figure 1).
However, in the nine months since the end of this study,
we have seen 13 more cases of community-onset invasive
MSSA infections, but only 2 cases of community-onset
invasive MRSA infections. The finding that MSSA was the
predominant pathogen of invasive staphylococcal infec-
tions might not be unexpected in a region of low MRSA
prevalence such as western Sweden [11]. A recent study of
community-associated S. aureus infections in Greece was
similar to our findings that MSSA predominated among
children with invasive infections, whereas CA-MRSA pre-
dominated among children with SSTIs [12]. McCaskill et
al. reported the increase of invasive infections caused by
MSSA, of which 35% of isolates were related to USA300,
the predominant clone of CA-MRSA [13]. It is plausible
that some USA300 strains may have lost their SCCmec ele-
ments, thereby becoming MSSA, or alternatively, the
ancestor of CA-MRSA USA300 was from an MSSA clone
that acquired its resistance before spreading in the com-
munity [10].
The majority of community-onset MRSA isolates from
hospitalized children, including individuals with health-
care-associated risk factors, were non-MDR – a character-
istic commonly observed in molecularly defined "CA-
MRSA" isolates. In this study, presence of healthcare-asso-
ciated risk factors was neither associated with multidrug-
resistant MRSA infections nor reliably predictive of the
susceptibility to methicillin in S. aureus isolates causing
community-onset infections. The use of healthcare-associ-
ated risk factors in exclusion criteria in studies of CA-
MRSA epidemiology may have underestimated the CA-
MRSA burden. Conversely, infections in patients who
have healthcare-associated risk factors are diverse and,
therefore, they are at increased risk for S. aureus infection
not only by MRSA, but by MSSA as well.
The emergence of MRSA infections in the community has
prompted clinicians to prescribe antibiotics that are active
against CA-MRSA in patients with any suspected S. aureus
infection. At CHOI, we have observed a significant
increase in the use of vancomycin as empiric therapy,
driven by growing concern for CA-MRSA. This practice has
contributed to inappropriate vancomycin use and has
been detrimental in several cases of invasive MSSA infec-
tions. A number of studies have demonstrated that vanco-
mycin is inferior to β-lactams for the treatment of invasive
MSSA infections [14-16]. Higher infection-related mortal-
Number of cases and admission rates (number of cases per 100 hospital admissions) of community-onset S. aureus infections  among hospitalized pediatric patients during the study period Figure 1
Number of cases and admission rates (number of cases per 100 hospital admissions) of community-onset S. 
aureus infections among hospitalized pediatric patients during the study period.
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ity has been reported in patients with invasive MSSA infec-
tions, even if vancomycin was switched to β-lactams once
the culture results became available [14]. Clindamycin,
another antibiotic that is active against many CA-MRSA
and MSSA isolates, has been used empirically [17]. How-
ever, based on the surveillance for antimicrobial resist-
ance among S. aureus circulating in our area (data not
shown), the percentage of clindamycin resistance in MSSA
isolates from 2005 to 2008 has been 20–25%. Because
invasive S. aureus infections are associated with increased
morbidity and mortality, and MSSA remains the predom-
inant cause of invasive S. aureus infections, it is prudent
for us to administer nafcillin in combination with vanco-
mycin in critically ill patients with invasive staphylococcal
infections, until susceptibility results are known. This rec-
ommendation has been supported and discussed else-
where [18,19].
In contrast, the majority of community-onset MRSA iso-
lates were non-MDR and were susceptible to clindamycin.
Clindamycin is the recommended empirical anti-staphy-
lococcal therapy for hospitalized pediatric patients with
clinical syndromes likely caused by CA-MRSA, such as
cutaneous abscesses or pneumonia with empyema. Its use
avoids unnecessary exposure to vancomycin. In addition,
the penetration of vancomycin into lung tissue and pul-
monary lining fluid has been reported to be relatively low
[20,21] and may limit the effectiveness of vancomycin in
the therapy of MRSA pneumonia. Moreover, clindamycin
inhibits toxin synthesis [22,23], including Panton-Valen-
tine leukocidin, a toxin which is associated with suppura-
tive skin and soft tissue infections and necrotizing
pneumonia [24-26]. It also may be responsible for the
increased virulence in some CA-MRSA isolates [1,27].
However, clindamycin is not appropriate for the treat-
ment of endocarditis because of a high rate of relapse, pre-
sumed to be due to its bacteriostatic action, nor is it
appropriate for meningitis because of poor central nerv-
ous system penetration. It should not be used as the
empiric monotherapy in critically ill patients. There is also
a risk of treatment failure during therapy if the isolate
Table 2: Characteristics of invasive infections and healthcare-associated risk factors.
MSSA MRSA
Invasive Infections
Bacteremia 17 10
Cervical lymphadenitis 94
Endocarditis 21
Pneumonia 27
Musculoskeletal infections 11 7
Others 6a 4b
Healthcare-associated Risk factors
Previous hospitalization 28 28
Previous surgery 20 15
Presence of an indwelling catheter or a percutaneous device 5 5
Underlying medical illnesses
Cystic fibrosis 11
Congenital heart diseases 4-
Diabetes 11
Immunosuppressive therapy 21
Hemophilia 1-
Renal failure -1
Short-bowel syndrome -1
aPericarditis (1), retropharyngeal abscess (1), staphylococcal toxic shock syndrome (1), chest wall abscess (1), suppurative parotitis (1), infection of 
the pace maker (1).
bMeningitis (1), dialysis catheter-related peritonitis (1), subhepatic abscess (1), infection of the implanted baclofen pump (1).
Table 3: Resistance patterns of MRSA isolates* stratified by 
healthcare-associated (HA) risk factors.
No. (%)
Patients with
HA risk factors
Patients without
HA risk factors
P
Non-MDR MRSA isolates n = 29 n = 70 0.20
Invasive infections 9 (9) 12 (12)
SSTIs 20 (20) 58 (59)
MDR MRSA isolates n = 4 n = 5 0.21
Invasive infections 3 (33) 1 (11)
SSTIs 1 (11) 4 (45)
* MDR phenotype was not determined in 2 MRSA isolates that were 
susceptible to clindamycin but resistant to erythromycin and 
tetracycline because of lack of D test results. These 2 MRSA isolates 
caused skin infections in patients without healthcare-associated risk 
factors.BMC Infectious Diseases 2009, 9:112 http://www.biomedcentral.com/1471-2334/9/112
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exhibits inducible clindamycin resistance [28]. At CHOI,
to minimize the development of antimicrobial resistance,
the empiric use of linezolid or daptomycin is discouraged.
Once the minimal inhibitory concentrations (MICs) are
available, for MRSA isolates in which vancomycin MICs
are 1.5–2 mg/L it would be appropriate to treat MRSA
infections with linezolid or daptomycin, since failure rate
is higher for such organisms treated with vancomycin.
There are limitations to our study. Strict inclusion and
exclusion criteria were used, thus possibly underestimat-
ing the true prevalence of community-onset S. aureus
infections among hospitalized children. Information
about other potentially important risk factors was not
always documented in medical records, particularly the
history of MRSA skin infections among patients or family
members. Nevertheless, the findings from our study have
clinically relevant implications for patient management.
While it is important that clinicians be aware of the emer-
gence of CA-MRSA infections, the diversity of epidemiol-
ogy of S. aureus infections should also be recognized.
Because antimicrobial resistance continues to evolve, it is
imperative to continue monitoring S. aureus infections at
the local level. This provides valuable data on resistance
trends and contributes to more effective treatment recom-
mendations for local and regional use.
Conclusion
We have described the characteristics of community-onset
S. aureus infections among hospitalized children in Cen-
tral Illinois. We found that MRSA is increasing as a cause
of skin and soft tissue infections, but that MSSA remains a
common cause of invasive infections. In our institution,
nafcillin in combination with vancomycin is recom-
mended empiric therapy in critically ill patients with sus-
pected invasive staphylococcal infections. Because up to
25% of MSSA circulating in our area are clindamycin-
resistant, clindamycin should be used cautiously as
empiric monotherapy in patients with suspected invasive
staphylococcal infections unless antimicrobial suscepti-
bility is known.
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